Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 8/20 | 0.42 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2324969 | 0.95 | MET (0.44) | PIM1METINPPL1ALKMAP4K1 | |
| Hydrochloric Acid SCHEMBL2325279 | 0.94 | MET (0.43) | PIM1METINPPL1ALKMAP4K1 | |
| SCHEMBL2321067 | 0.90 | INPPL1 (0.50) | PIM1METINPPL1ALKMAP4K1 | |
| SCHEMBL2324841 | 0.90 | MAP4K3 (0.47) | PIM1METALKMAP4K1MAP4K3 | |
| Hydrochloric Acid SCHEMBL2324061 | 0.89 | INPPL1 (0.49) | PIM1METINPPL1ALKMAP4K1 | |
| SCHEMBL2320474 | 0.88 | MAP4K1 (0.53) | PIM1METALKMAP4K1MAP4K3 | |
| Hydrochloric Acid SCHEMBL13834975 | 0.87 | MAP4K1 (0.52) | PIM1METALKMAP4K1MAP4K3 | |
| SCHEMBL2330194 | 0.86 | MET (0.42) | METIRAK4EGFR | |
| SCHEMBL12439733 | 0.81 | MET (0.46) | METMAP4K3EGFR | |
| SCHEMBL12441209 | 0.81 | MET (0.47) | METINPPL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011095196-A1 | HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295902-A1 | Hetaryl-[1,8]naphthyridine derivatives | ATP5F1A, ATP5ME, ATP5F1D | PIM1 2999/4885MET 2262/4885INPPL1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.